CRYO-CELL International, Inc. (OTCMKTS:CCEL) CEO David Portnoy bought 3,800 shares of the business’s stock in a transaction on Thursday, January 31st. The stock was bought at an average price of $6.75 per share, for a total transaction of $25,650.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Shares of CRYO-CELL International stock opened at $7.50 on Wednesday. CRYO-CELL International, Inc. has a fifty-two week low of $6.03 and a fifty-two week high of $9.64. The company has a market capitalization of $58.04 million, a price-to-earnings ratio of 26.79 and a beta of 0.09.
CRYO-CELL International Company Profile
Cryo-Cell International, Inc engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases.
Recommended Story: What is a bull market?
Receive News & Ratings for CRYO-CELL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRYO-CELL International and related companies with MarketBeat.com's FREE daily email newsletter.